Physician profile
Danielle R Smith
NPI 1538642988
$6,656.35
in general payments reported to CMS, 2019-2025
32 companies · $1,562 in 2025
The $1,562 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $455 · 2022: $905 · 2023: $1,780 · 2024: $1,953 · 2025: $1,562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,287 · Education: $9.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,286.75 |
| Education | $9.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,027.51 | 2022-2025 | Aveir, Ensite, Gallant |
| E.R. Squibb & Sons, L.L.C. | $771.58 | 2021-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $406.18 | 2022-2024 | Cobalt Dr Mri Surescan, Azure Xt Dr Mri Surescan, Mycarelink |
| Boehringer Ingelheim Pharmaceuticals, INC. | $362.84 | 2021-2024 | Jardiance |
| Genzyme Corporation | $252.97 | 2023-2024 | |
| Edwards Lifesciences Corporation | $252.48 | 2024-2025 | Sapien 3 Ultra Resilia |
| Gilead Sciences, INC. | $245.76 | 2024-2025 | Epclusa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $242.92 | 2021-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $221.84 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $170.83 | 2022-2024 | Xarelto |
| Grifols USA, LLC | $125.65 | 2024 | Xembify |
| Genentech USA, INC. | $124.99 | 2021 | |
| Paratek Pharmaceuticals, INC. | $124.99 | 2023 | Nuzyra |
| Amgen INC. | $124.97 | 2024 | Repatha |
| Merck Sharp & Dohme LLC | $122.88 | 2025 | Capvaxive |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $121.24 | 2023 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $120.73 | 2024 | Farxiga |
| Abiomed | $107.25 | 2024 | Impella |
| Boston Scientific Corporation | $99.80 | 2021-2022 | |
| Kyowa Kirin, INC. | $99.66 | 2024 | |
| Phadia US INC. | $96.29 | 2022 | |
| Alkermes, INC. | $94.08 | 2025 | Lybalvi |
| Janssen Biotech, INC. | $74.86 | 2025 | Tremfya |
| Pfizer INC. | $49.70 | 2023 | |
| Abbvie INC. | $44.89 | 2023 | |
| Lantheus Medical Imaging, INC. | $36.91 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.01 | 2025 | Gattex |
| Pharmacosmos Therapeutics INC. | $24.27 | 2024 | Monoferric |
| Fresenius Kabi USA, LLC | $23.42 | 2025 | Smoflipid |
| Atricure, INC. | $22.19 | 2024 | |
| Tersera Therapeutics LLC | $19.04 | 2025 | Xermelo |
| Kiniksa Pharmaceuticals, LTD. | $15.62 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.